Cartesian Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $78 | $947 | $452 |
Gross Profit | 78 | 947 | -12,345 | |
EBITDA | 17,421 | -38,567 | -101,161 | -35,296 |
EBIT | 16,621 | -39,182 | -101,769 | -35,902 |
Net Income | 13,720 | -39,182 | -92,576 | -35,902 |
Net Change In Cash | 0 | 78 | 947 | 452 |
Free Cash Flow | -20,898 | -22,162 | -18,204 | -16,892 |
Cash | 147,606 | 118,641 | 125,139 | 143,384 |
Basic Shares | 29,860 | 26,855 | 25,973 | 26,002 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,797 | $38,913 | $26,004 | $110,777 |
Gross Profit | 2,797 | 38,913 | 26,004 | 108,740 |
EBITDA | -136,536 | -75,986 | -235,034 | 39,838 |
EBIT | -139,495 | -77,137 | -235,877 | 37,801 |
Net Income | -130,302 | -77,424 | -219,710 | 35,379 |
Net Change In Cash | 2,797 | 38,913 | 26,004 | 110,777 |
Cost of Revenue | -7,418 | |||
Free Cash Flow | -79,395 | -32,767 | -51,367 | -32,832 |
Cash | 125,139 | 212,610 | 76,911 | 106,438 |
Basic Shares | 25,973 | 23,689 | 5,170 | 4,052 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.46 |
2026-03-31 | -$0.95 |
2025-12-31 | -$2.70 |
2025-09-30 | -$0.73 |